Logo image of EXOZ

EXOZYMES INC (EXOZ) Stock Fundamental Analysis

NASDAQ:EXOZ - Nasdaq - US4618741098 - Common Stock - Currency: USD

9.25  0 (0%)

Fundamental Rating

3

Taking everything into account, EXOZ scores 3 out of 10 in our fundamental rating. EXOZ was compared to 558 industry peers in the Biotechnology industry. EXOZ has a great financial health rating, but its profitability evaluates not so good. EXOZ is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EXOZ had negative earnings in the past year.
In the past year EXOZ has reported a negative cash flow from operations.
EXOZ Yearly Net Income VS EBIT VS OCF VS FCFEXOZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

EXOZ has a Return On Assets (-58.21%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -75.54%, EXOZ is in line with its industry, outperforming 52.69% of the companies in the same industry.
Industry RankSector Rank
ROA -58.21%
ROE -75.54%
ROIC N/A
ROA(3y)-51.41%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EXOZ Yearly ROA, ROE, ROICEXOZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EXOZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EXOZ Yearly Profit, Operating, Gross MarginsEXOZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, EXOZ has more shares outstanding
EXOZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EXOZ Yearly Shares OutstandingEXOZ Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M
EXOZ Yearly Total Debt VS Total AssetsEXOZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

EXOZ has an Altman-Z score of 14.75. This indicates that EXOZ is financially healthy and has little risk of bankruptcy at the moment.
EXOZ has a Altman-Z score of 14.75. This is amongst the best in the industry. EXOZ outperforms 90.86% of its industry peers.
EXOZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.75
ROIC/WACCN/A
WACCN/A
EXOZ Yearly LT Debt VS Equity VS FCFEXOZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 6.52 indicates that EXOZ has no problem at all paying its short term obligations.
EXOZ has a Current ratio of 6.52. This is in the better half of the industry: EXOZ outperforms 63.80% of its industry peers.
A Quick Ratio of 6.52 indicates that EXOZ has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.52, EXOZ is in the better half of the industry, outperforming 64.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.52
Quick Ratio 6.52
EXOZ Yearly Current Assets VS Current LiabilitesEXOZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for EXOZ have decreased strongly by -256.10% in the last year.
EPS 1Y (TTM)-256.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EXOZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EXOZ Price Earnings VS Forward Price EarningsEXOZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EXOZ Per share dataEXOZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXOZ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXOZYMES INC

NASDAQ:EXOZ (7/18/2025, 8:00:02 PM)

9.25

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)N/A N/A
Inst Owners0.92%
Inst Owner ChangeN/A
Ins Owners24.95%
Ins Owner Change0.72%
Market Cap77.42M
AnalystsN/A
Price TargetN/A
Short Float %0.72%
Short Ratio1.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.72
P/tB 8.72
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.21%
ROE -75.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.41%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 101.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.52
Quick Ratio 6.52
Altman-Z 14.75
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)140.25%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-256.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.81%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-230.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-505.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-620.26%
OCF growth 3YN/A
OCF growth 5YN/A